Ovid Therapeutics (OVID) Total Current Liabilities (2016 - 2026)

Ovid Therapeutics (OVID) has reported Total Current Liabilities for 11 consecutive years, with $10.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 11.83% year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2026 stood at $10.0 million (up 11.83% YoY), and the FY2025 full-year result was $8.3 million, down 21.23% from the prior year.
• Total Current Liabilities declined to $10.0 million in Q2 2026 per OVID's latest filing, from $15.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $15.7 million in Q1 2026 and bottomed at $6.7 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $9.9 million across 5 years, with a median of $9.3 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities slumped 52.75% in 2022, then soared 69.21% in 2026.
• Over 5 years, Total Current Liabilities stood at $7.0 million in 2022, then soared by 64.1% to $11.5 million in 2023, then retreated by 8.29% to $10.5 million in 2024, then slipped by 21.23% to $8.3 million in 2025, then grew by 20.42% to $10.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $10.0 million, $15.7 million, and $8.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.